Loading clinical trials...
Loading clinical trials...
A Single-Arm Phase II Study of Isatuximab With Carfilzomib and Pomalidomide in Relapsed or Refractory Multiple Myeloma
Conditions
Interventions
Carfilzomib
Isatuximab
+1 more
Locations
1
United States
OHSU Knight Cancer Institute
Portland, Oregon, United States
Start Date
June 14, 2022
Primary Completion Date
October 15, 2026
Completion Date
February 21, 2029
Last Updated
December 18, 2025
NCT05312255
NCT04508790
NCT04640779
NCT04756401
NCT05288062
NCT03015792
Lead Sponsor
OHSU Knight Cancer Institute
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions